ICML 2019: "TELLOMAK” clinical trial design and rationale and KOL webcast
A KOL webcast and conference call was held on Thursday, June 20, 2019
Welcome to Innate Pharma
Scroll
About Innate Pharma
Innate Pharma S.A. is a commercial stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.
Headlines
Publication in Cell on innovative multifunctional NKp46 NK cell engagers (NKCEs)
May 31, 2019
Innate Pharma SA announced the publication of data demonstrating the potential of multifunctional NKp46 NKCEs in cancer immunotherapy in Cell
Innate Pharma SA announced the publication of data demonstrating the potential of multifunctional NKp46 NKCEs in cancer immunotherapy in Cell
Innate Pharma announces publication of IPH4102 Phase I clinical trial results for CTCL in the Lancet Oncology
Publication in The Lancet Oncology of the results from the completed Phase I dose-escalation and expansion clinical trial of IPH4102 in advanced CTCL patients.
Upcoming events
"20 years on Immuno-Oncology" Event organized by Innate Pharma
September 23, 2019
ESMO Congress 2019 | Barcelona, Spain
September 27, 2019 to October 1, 2019
Journée portes ouvertes pour la Fête de la Science
October 9, 2019